Compare ADMA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADMA | BEAM |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2012 | 2019 |
| Metric | ADMA | BEAM |
|---|---|---|
| Price | $13.26 | $20.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $18.00 | ★ $49.85 |
| AVG Volume (30 Days) | ★ 3.8M | 2.1M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $42,219,783.00 | $24,000.00 |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | $14.91 | N/A |
| P/E Ratio | $23.39 | ★ N/A |
| Revenue Growth | ★ 43.85 | 33.33 |
| 52 Week Low | $7.21 | $20.44 |
| 52 Week High | $20.46 | $38.26 |
| Indicator | ADMA | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 35.27 |
| Support Level | $7.84 | N/A |
| Resistance Level | $13.77 | $27.30 |
| Average True Range (ATR) | 0.74 | 1.72 |
| MACD | 0.02 | -0.61 |
| Stochastic Oscillator | 74.43 | 3.31 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.